Featured Research

from universities, journals, and other organizations

New drug a potential treatment for Type 2 diabetes

Date:
September 20, 2010
Source:
Garvan Institute of Medical Research
Summary:
Australian scientists have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes. Researchers tested the anti-inflammatory drug which is undergoing clinical trials for other diseases, on mice being fed high-fat diets.

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

Drs Georgia Frangioudakis and Carsten Schmitz-Peiffer from Sydney's Garvan Institute of Medical Research, tested the anti-inflammatory drug which is undergoing clinical trials for other diseases, on mice being fed high-fat diets. Their findings are published in the journal Endocrinology, now online.

"This is the first time it has been suggested that Lisofylline could be useful in treating Type 2 diabetes," said Dr Schmitz-Peiffer. "We believe it works by preventing the build up of certain by-products of fat metabolism."

"Fats build up in the muscle and liver cells of obese people or high-fat fed mice. When those fats are metabolised, their breakdown products prevent the normal movement of glucose into cells."

The hormone insulin is produced after we eat to move glucose from our bloodstream into our cells for energy. When people get fat, that process becomes compromised and they develop 'glucose intolerance', or 'insulin resistance', precursors of Type 2 diabetes.

"The blood sugar levels of people with insulin resistance take a long time to come down after eating because glucose can't get into their cells," explained Schmitz-Peiffer. "High blood sugar can lead to many unwelcome complications, such as kidney failure and blindness. So it's something you want to control if you possibly can."

"Certain drugs can prevent the various metabolites of fat from accumulating, and we were interested in blocking development of one known as 'Ceramide'."

"A lot of studies have shown that a build up of Ceramide in muscle correlates at least with a build up of insulin resistance."

"In the absence of Ceramide, the transmission of signals between molecules inside cells improves, and so does the ability of insulin to be effective."

"As it happens, Lisofylline is effective in preventing the build up of a number of fat metabolites, including Ceramide. While we don't yet understand all the mechanisms, we believe the blocking of Ceramide may have something to do with the drug's anti-inflammatory properties."

"We tested Lisofylline and another fat metabolism inhibitor under different dietary conditions, and Lisofylline was able to improve insulin action under all of them, making it a useful potential treatment for obesity-related insulin resistance."

"Lisofylline has already undergone Phase 1 clinical trials, and has been shown to be safe when used in healthy subjects. It is undergoing Phase 2 clinical trials for other purposes at the moment."

"These new results suggest that the development of Lisofylline, or other drugs that might be orally bioavailable with the same spectrum of activity, may be a novel approach to the treatment for Type 2 diabetes."


Story Source:

The above story is based on materials provided by Garvan Institute of Medical Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. G. Frangioudakis, J. Garrard, K. Raddatz, J. L. Nadler, T. W. Mitchell, C. Schmitz-Peiffer. Saturated- and n-6 Polyunsaturated-Fat Diets Each Induce Ceramide Accumulation in Mouse Skeletal Muscle: Reversal and Improvement of Glucose Tolerance by Lipid Metabolism Inhibitors. Endocrinology, 2010; 151 (9): 4187 DOI: 10.1210/en.2010-0250

Cite This Page:

Garvan Institute of Medical Research. "New drug a potential treatment for Type 2 diabetes." ScienceDaily. ScienceDaily, 20 September 2010. <www.sciencedaily.com/releases/2010/09/100920080120.htm>.
Garvan Institute of Medical Research. (2010, September 20). New drug a potential treatment for Type 2 diabetes. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/09/100920080120.htm
Garvan Institute of Medical Research. "New drug a potential treatment for Type 2 diabetes." ScienceDaily. www.sciencedaily.com/releases/2010/09/100920080120.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins